Health
GC Pharma sticks to plasma therapy study despite global trial failures – Korea Biomedical Review
GC Pharma said it would continue to develop hyperimmune globulin drug for Covid-19 despite the recent statement by CoVig-19 Plasma Alliance that it confirmed disappointing…
GC Pharma said it would continue to develop hyperimmune globulin drug for Covid-19 despite the recent statement by CoVig-19 Plasma Alliance that it confirmed disappointing results in phase 3 clinical trials.
Takeda, one of the co-leaders of the CoVig-19 Plasma Alliance, said Wednesday that the group has completed the phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (ITAC) clinical trials and decided to end the year-long collaboration as it did not meet the endpoint in the study.
…
-
General16 hours agoAustralia Kangaroos lose Xavier Coates and Zac Lomax ahead of rugby league Ashes in England
-
Noosa News23 hours agoSuncorp Stadium upgrades to rival Sydney as seat capacity and infrastructure prioritised
-
General21 hours agoRescuers pull children from the rubble of Indonesian boarding school collapse
-
Noosa News23 hours ago‘The Book of Mormon’ Returns to Melbourne and Brisbane in 2026